Study guide
23.3 Glaucoma Medications: Classes, Mechanisms & Side Effects
IJCAHPO Certified Ophthalmic Medical Technologist COMT
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The COMT Examination, Eligibility & Certification Requirements
1.1 The 190-Question Multiple-Choice Examination & the 22 Official Content Areas 1.2 The COT Skill Evaluation & the COMT Performance Test 1.3 Eligibility Pathways, Fees, Timelines & Recertification
2 Chapter 2: General Medical Knowledge I — Ocular Anatomy & Physiology
2.1 Orbit, Eyelids, Lacrimal System, Conjunctiva & Extraocular Muscles 2.2 Cornea, Sclera, Anterior Chamber, Angle, Aqueous Dynamics & Crystalline Lens 2.3 Uvea, Retina, Vitreous, Optic Nerve, Ocular Circulation & the Visual Pathway
3 Chapter 3: General Medical Knowledge II — Eye Disease, Systemic Manifestations, Terminology & Safety
3.1 Frequently Encountered Eye Conditions by Structure & Inflammation Versus Infection 3.2 Body Systems & the Ocular Manifestations of Systemic Disease 3.3 Medical Terminology, Approved Abbreviations, Hazardous Waste & Clinic Safety
4 Chapter 4: Ophthalmic History Taking & Clinical Documentation
4.1 The Five History Domains: Ocular, Medical, Medication, Social & Family 4.2 Charting Conventions, Scribing & the Electronic Medical Record
5 Chapter 5: Visual Assessment, Accommodative Testing & Low Vision
5.1 Measuring Acuity at Every Level & in Preliterate, Illiterate and Non-Verbal Patients 5.2 Stereoacuity, Near Point of Accommodation, Near Point of Convergence & the AC/A Ratio 5.3 Low Vision Assessment, Magnification Calculation & Device Instruction
6 Chapter 6: Tonometry, Keratometry & Pupil Measurement
6.1 Goldmann Applanation Tonometry: Technique, Sources of Error & the Imbert-Fick Principle 6.2 Hand-Held Applanators, Non-Contact Tonometry, Rebound Tonometry & Disinfection 6.3 Manual & Automated Keratometry: Technique, Readings and Interpretation 6.4 Pupil Measurement, Shape, Reactivity & Evaluating Anisocoria
7 Chapter 7: Lensometry, Spectacle Optics & Prescription Analysis
7.1 Manual Lensometry: Eyepiece Focus, Neutralising Sphere, Cylinder & Axis 7.2 Neutralising Reading Adds: Bifocal, Trifocal, Progressive & Determining the Near Add 7.3 Identifying & Measuring Prism: Ground-In, Decentration, Fresnel Press-On & Slab-Off 7.4 Transposition, Spherical Equivalent, Vertex Distance & Prescription Components 7.5 The Geneva Lens Clock, Lens Materials, Progressive Markings & Spectacle Adjustment
8 Chapter 8: Refraction, Retinoscopy & Refinement
8.1 Autorefraction, Refractive Error Types & Establishing an Objective Starting Point 8.2 Streak Retinoscopy: With Motion, Against Motion, Neutralisation & Working Distance 8.3 Subjective Refinement: Fogging, Jackson Cross Cylinder, Duochrome & Binocular Balance 8.4 Near Add Determination, Vertex Recording & Refraction in Difficult Situations
9 Chapter 9: Ocular Motility, Strabismus & Advanced Optics
9.1 Ocular Kinematics: Ductions, Versions, Vergences, Hering's & Sherrington's Laws 9.2 Quantitative Strabismus Measurements: Alternate Cover Test, Prism Cover Test & Lancaster Red-Green / Hess Screen 9.3 Cranial Nerve Palsies (CN III, IV, VI), Restrictive Myopathies & Forced Duction Testing 9.4 Clinical Optics, Prentice's Rule, Slab-Off Prisms & Wavefront Aberrations
10 Chapter 10: Sensory Fusion Testing, Nystagmus, Amblyopia & Vergence Therapy
10.1 Sensory Fusion Testing: Worth 4-Dot, Maddox Rod & Bagolini Lenses 10.2 Hirschberg, Krimsky, Brückner & Fusional Vergence Amplitudes 10.3 Nystagmus, Amblyopia Therapy & Convergence Training
11 Chapter 11: Advanced Visual Fields & Neuro-Ophthalmic Evaluation
11.1 Amsler Grid & Confrontation Visual Field Testing 11.2 Automated Static Perimetry: HFA Strategies (SITA Standard, SITA Fast), Reliability Indices & Statpac Analysis 11.3 Visual Field Defect Patterns: Glaucomatous Nerve Fiber Bundle Deficits vs. Retinal Pathology 11.4 Kinetic Perimetry (Goldmann Perimetry) & Neurological Visual Pathway Defect Localization 11.5 Pupillary Pathways, RAPD Quantitation with Neutral Density Filters & Pharmacologic Testing
12 Chapter 12: Supplemental Testing — Glare, PAM, Colour Vision, Tear Film & Slit Lamp Technique
12.1 Glare Testing, Potential Acuity Meter & Contrast Sensitivity 12.2 Colour Vision: Pseudoisochromatic Plates, Farnsworth-Munsell D-15 & the 100-Hue Test 12.3 Tear Film Assessment: Schirmer, Tear Break-Up Time, Vital Dyes & Corneal Sensitivity 12.4 Slit Lamp Technique, Slit Lamp Lenses, Direct Ophthalmoscopy & Pen Light Examination 12.5 Exophthalmometry, Head & Posture Assessment and Wavefront Diagnostics
13 Chapter 13: Full-Field Electroretinography & ISCEV Protocols
13.1 Retinal Neurophysiology & Electrophysiologic Origin of Waveforms 13.2 ISCEV Standard Full-Field ERG Protocol & Electrode Systems 13.3 Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response 13.4 Light-Adapted (Photopic) Testing: Cone Response, 30-Hz Flicker & Oscillatory Potentials
14 Chapter 14: Advanced Electrophysiologic Testing (mfERG, PERG, VEP, EOG)
14.1 Multifocal Electroretinogram (mfERG): Topographic Retinal Mapping 14.2 Pattern Electroretinogram (PERG): Ganglion Cell & Macular Function 14.3 Visual Evoked Potentials (VEP): Flash, Pattern & Visual Pathway Integrity 14.4 Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics
15 Chapter 15: Fluorescein Angiography Principles & Technique
15.1 Fluorescein Angiography Principles, Exciter/Barrier Filters & Injection Protocol 15.2 Normal Transit Phases & Retinal/Choroidal Circulation Hemodynamics 15.3 Adverse Reactions, Patient Safety & Emergency Management
16 Chapter 16: Angiographic Interpretation & Pathology
16.1 Hyperfluorescence Mechanisms: Leakage, Staining, Pooling, Window Defects & Autofluorescence 16.2 Hypofluorescence Mechanisms: Vascular Non-Perfusion & Blocking Defects 16.3 Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology
17 Chapter 17: Advanced Fundus Imaging & Optical Coherence Tomography
17.1 Fundus Autofluorescence (FAF) & Ultra-Widefield Fundus Imaging 17.2 Spectral-Domain and Swept-Source OCT: Retinal Layer Architecture & Quantitative Analysis 17.3 Enhanced Depth Imaging (EDI-OCT) & Anterior Segment OCT (AS-OCT) 17.4 Optical Coherence Tomography Angiography (OCTA): Chorioretinal Plexuses & Biomarkers
18 Chapter 18: Ophthalmic Photography & Videography
18.1 The Fundus Camera: Optics, Alignment & Correcting Artefacts 18.2 Standard Fundus Photography: ETDRS Fields, Stereo Pairs, Red-Free & Wide-Field Imaging 18.3 Slit Lamp & Anterior Segment Photography 18.4 External Photography, Nine-Gaze Motility Documentation & Image Management
19 Chapter 19: Ophthalmic Echography (A-Scan, B-Scan & UBM)
19.1 Physics of Ophthalmic Ultrasound, Acoustic Impedance & Probe Transducers 19.2 Standardized Diagnostic A-Scan: Acoustic Spikes, Tissue Reflectivity & Attenuation 19.3 Diagnostic B-Scan Echography: Topographic, Kinetic & Quantitative Vitreoretinal Evaluation 19.4 Ultrasound Biomicroscopy (UBM): Anterior Segment Anatomy, Angle Pathology & Ciliary Body Imaging
20 Chapter 20: Biometry, Topography & Corneal Analysis
20.1 Optical Biometry vs. Immersion/Contact Ultrasound Biometry 20.2 Intraocular Lens (IOL) Power Calculation Formulas & Post-Refractive Adjustments 20.3 Corneal Topography, Scheimpflug Tomography & Keratoconus Screening 20.4 Corneal Pachymetry, Endothelial Specular Microscopy & Anterior Chamber Depth
21 Chapter 21: Rigid Gas Permeable & Specialty Lens Fitting
21.1 Rigid Gas Permeable (RGP) Material Properties, Dk/t & Oxygen Permeability 21.2 RGP Base Curve Selection, Diagnostic Fitting & Fluorescein Pattern Evaluation 21.3 Scleral Contact Lens Design, Sagittal Depth Fitting & Clearance Evaluation 21.4 Keratoconus, Irregular Corneas & Hybrid Contact Lens Systems
22 Chapter 22: Toric, Multifocal, Therapeutic Lenses & Complications
22.1 Toric Soft Contact Lens Dynamics, Stabilization Techniques & LARS Rule 22.2 Presbyopic & Multifocal Contact Lens Systems: Simultaneous vs. Translating Designs 22.3 Therapeutic Bandage Contact Lenses, Amniotic Membranes & Orthokeratology 22.4 Contact Lens-Induced Pathology, Giant Papillary Conjunctivitis & Infectious Keratitis
23 Chapter 23: Ocular Pharmacology
23.1 Routes of Drug Delivery, Prescription Components & Instillation Technique 23.2 Mydriatics, Cycloplegics, Anaesthetics & Diagnostic Agents 23.3 Glaucoma Medications: Classes, Mechanisms & Side Effects 23.4 Anti-Infectives, Corticosteroids, NSAIDs, Allergy Agents, Lubricants, Supplements & Anti-VEGF
24 Chapter 24: Microbiology & Ocular Specimen Collection
24.1 Types of Microorganisms & Pathways of Disease Transmission 24.2 Assisting with Conjunctival & Corneal Specimen Collection
25 Chapter 25: Anterior Segment, Glaucoma & Refractive Surgery
25.1 Advanced Phacoemulsification, Surgical Steps, Fluidics & Complication Management 25.2 Premium Intraocular Lenses: Toric, Multifocal, EDOF & Lens Exchange 25.3 Glaucoma Surgical Procedures: Trabeculectomy, Aqueous Shunts & MIGS Devices 25.4 Laser In Situ Keratomileusis (LASIK), PRK, SMILE & Phakic IOLs
26 Chapter 26: Vitreoretinal, Corneal & Trauma Surgery
26.1 Pars Plana Vitrectomy (PPV), Scleral Buckling & Intraocular Tamponades (Gas/Silicone Oil) 26.2 Corneal Transplantation: Penetrating Keratoplasty (PKP) & Lamellar Keratoplasty (DSAEK, DMEK, DALK) 26.3 Ocular Trauma Repair: Open Globe Management, Hyphema, Vitreous Loss & Endophthalmitis Protocol
27 Chapter 27: Surgical Asepsis, Instrumentation & Laser Procedures
27.1 Operating Room Sterilization, Aseptic Field Maintenance & Universal Precautions 27.2 Microsurgical Instrumentation, Maintenance & Sharps Safety 27.3 Ophthalmic Laser Physics, Delivery Systems & Safety (Nd:YAG, Argon/FD-Nd:YAG, SLT)
28 Chapter 28: Ophthalmic Patient Services & Education
28.1 Communicating with Patients, Families and Colleagues, and Handling Dissatisfaction 28.2 Patient Education & Counselling on Conditions, Medications, Tests and Results 28.3 Ophthalmic Emergencies, First Aid, Vital Signs & CPR 28.4 Triage, Urgency-Based Scheduling, Patient Flow & Telephone Management 28.5 Dressings and Shields, Prosthetics, Legal Forms, Referrals & Reimbursement Support
29 Chapter 29: Clinic Operations — Equipment Maintenance, Ethics, Coding & Compliance
29.1 Equipment Maintenance, Calibration, Emergency Equipment & Inventory 29.2 Confidentiality, Informed Consent, Scope of Practice & Ethical Standards 29.3 Coding, Scribing Compliance, Quality Assurance & Regulatory Requirements
23.3 Glaucoma Medications: Classes, Mechanisms & Side Effects
Key Takeaways Explain This Topic AI
Prostaglandin analogues increase uveoscleral outflow, are dosed once nightly and are the usual first-line agent.
Prostaglandin analogues cause iris and periocular pigmentation and eyelash growth, which are cosmetic but permanent for the iris.
Topical beta-blockers reduce aqueous production and are contraindicated in asthma, COPD, bradycardia and heart block.
Alpha-2 agonists both reduce production and increase uveoscleral outflow; brimonidine is contraindicated in infants because of central nervous system depression.
Carbonic anhydrase inhibitors are sulphonamide derivatives, and oral acetazolamide causes paraesthesia, malaise and metabolic acidosis.
Last updated: September 2026
The two levers
Every glaucoma drug does one of two things: reduces aqueous production or increases aqueous outflow . Knowing which lever a drug pulls predicts its side effects.
- Class Mechanism Typical dosing
- Prostaglandin analogues Increase uveoscleral outflow Once nightly
- Beta-blockers Reduce production Once or twice daily
- Alpha-2 agonists Reduce production and increase uveoscleral outflow Two or three times daily
- Carbonic anhydrase inhibitors Reduce production Topical two or three times daily; oral
- Rho kinase inhibitors Increase trabecular outflow Once nightly
- Miotics (cholinergics) Increase trabecular outflow by ciliary muscle contraction Up to four times daily
- Hyperosmotics Draw water osmotically from the vitreous Acute use only
- Prostaglandin analogues
Examples: latanoprost, travoprost, bimatoprost, tafluprost, latanoprostene bunod.
Why they are first-line: the strongest single-agent pressure reduction, once-nightly dosing that supports compliance, and minimal systemic effect.
Ocular side effects — and these generate patient complaints, so counsel in advance:
- Increased iris pigmentation — permanent, most noticeable in hazel or mixed-colour irides
- Periocular skin hyperpigmentation — usually reversible on stopping
- Eyelash growth — longer, thicker, darker lashes; the basis of a cosmetic product
- Conjunctival hyperaemia — common early, often settles
Prostaglandin-associated periorbitopathy — deepening of the upper lid sulcus, periorbital fat atrophy, ptosis; asymmetric appearance in unilateral use
Reactivation of herpes simplex keratitis ; cystoid macular oedema in predisposed eyes, especially aphakia and pseudophakia with a compromised capsule
Beta-blockers
Examples: timolol (non-selective), levobunolol, carteolol, betaxolol ( beta-1 selective ).
Systemic side effects are the examinable point. Topical timolol is absorbed through the nasal mucosa into the circulation without first-pass metabolism and can cause:
- Bronchospasm — potentially fatal in asthma
- Bradycardia, heart block, hypotension, worsening heart failure
- Fatigue, depression, reduced exercise tolerance
- Masking of hypoglycaemic symptoms in insulin-treated diabetes
- Reduced libido
Contraindications: asthma, chronic obstructive pulmonary disease, sinus bradycardia, second or third degree heart block, cardiogenic shock and uncompensated heart failure. Betaxolol , being beta-1 selective, is relatively safer in reactive airways disease but is not risk-free.
This is why the medication and medical history matter. A patient handed a timolol sample without anyone asking about asthma is a genuine and documented cause of harm. Always teach punctal occlusion with a topical beta-blocker.
Tachyphylaxis — a diminishing response over weeks to months — is described with beta-blockers and is one reason for apparent treatment failure.
Alpha-2 adrenergic agonists
Examples: brimonidine, apraclonidine.
Mechanism: reduce aqueous production and increase uveoscleral outflow.
Side effects: ocular allergy is common — a follicular conjunctivitis developing weeks to months into treatment and the usual reason for discontinuation; also dry mouth, fatigue, drowsiness and hypotension.
Critical contraindication: brimonidine is contraindicated in infants and young children because it crosses the blood-brain barrier and causes central nervous system depression, apnoea, bradycardia and hypotension. It is also avoided with monoamine oxidase inhibitors.
Apraclonidine is used mainly for short-term pressure spikes, such as after laser trabeculoplasty or YAG capsulotomy, because tachyphylaxis and allergy limit chronic use. It also has the diagnostic role in Horner syndrome described earlier.
Carbonic anhydrase inhibitors
Topical: dorzolamide, brinzolamide. Oral: acetazolamide, methazolamide.
Mechanism: inhibit carbonic anhydrase in the ciliary epithelium, reducing aqueous production.
Topical side effects: stinging and a bitter metallic taste (from nasolacrimal drainage to the pharynx), transient blur, superficial punctate keratopathy. Use with caution in low endothelial cell counts, where corneal decompensation has been reported.
Oral acetazolamide side effects — a favourite examination topic:
- Paraesthesia of fingers, toes and around the mouth — almost universal
- Malaise, fatigue, anorexia, weight loss, depression — the "symptom complex"
- Metabolic acidosis and hypokalaemia
- Renal stones
- Gastrointestinal upset, altered taste (carbonated drinks taste odd)
- Rarely aplastic anaemia and Stevens-Johnson syndrome
All carbonic anhydrase inhibitors are sulphonamide derivatives — document a sulfa allergy carefully. Avoid in significant renal or hepatic impairment and in sickle cell disease, where acidosis promotes sickling.
Rho kinase inhibitors
Example: netarsudil.
Mechanism: relax the trabecular meshwork and increase conventional outflow; may also reduce episcleral venous pressure.
Side effects: conjunctival hyperaemia in the majority of patients , corneal verticillata (whorl-like deposits that are benign and reversible), and subconjunctival haemorrhage . Patients must be warned about the redness or they will stop the drug.
Miotics
Example: pilocarpine.
Mechanism: contracts the ciliary muscle, which pulls on the scleral spur and opens the trabecular meshwork; also contracts the pupil sphincter, which pulls the peripheral iris away from the angle — the reason it is used in angle closure .
Side effects: miosis causing dim vision and reduced night vision , accommodative spasm and brow ache (marked in young patients), induced myopia, and an increased risk of retinal detachment in predisposed eyes. Four-times-daily dosing makes compliance poor. Systemic cholinergic effects — sweating, salivation, bradycardia, bronchospasm, gastrointestinal cramps — occur with excess.
Hyperosmotics
Examples: intravenous mannitol, oral glycerol, oral isosorbide.
Use: acute angle closure and other acute pressure emergencies, by osmotically drawing water out of the vitreous.
Cautions: volume overload and pulmonary oedema in cardiac or renal failure; glycerol is metabolised to glucose and must be used cautiously in diabetes, where isosorbide is preferred.
Fixed combinations
Combination bottles — a beta-blocker with a carbonic anhydrase inhibitor, a beta-blocker with brimonidine, a beta-blocker with a prostaglandin — reduce the drop burden and improve compliance, and eliminate the washout problem between drops. Their side-effect profiles are the sum of their components, so every contraindication of each component applies.